

INVITATION TO SATELLITE SYMPOSIUM

ISTH CONGRESS 2017 • 8 - 13 JULY 2017 • BERLIN, GERMANY

The Continuing Challenge of Venous Thromboembolism: Insights from the GARFIELD-VTE Registry

Wednesday 12 July 2017 • 13:15 – 14:30 • Room Helsinki 2

Dear colleagues,

It is our pleasure to invite you to the 1st GARFIELD-VTE symposium, which will be held at the ISTH Congress 2017. GARFIELD-VTE (Global Anticoagulant Registry in the FIELD–Venous Thromboembolism) is a global outcomes registry in 28 countries with over 10,874 patients enrolled thus far. The registry is supported by an unrestricted research grant from Bayer AG (Berlin, Germany).

At this year's satellite symposium we will explore the following questions using data from patients with Venous Thromboembolism (VTE) in GARFIELD-VTE:

- What is the burden of VTE?
- What are the characteristics of patients and their treatments?
- How is cancer-associated thrombosis managed?
- What are the outcomes of real world studies?

We look forward to welcoming you and your participation in this symposium.

Sincerely,

Rt Hon Professor the Lord Kakkar, Chair



Agenda

13:15 – 13:30	Understanding the Global Burden – Garfield VTE A K Kakkar (UK)
13:30 – 13:40	VTE: A Chronic Disease – Implications for Extended Duration Anticoagulation S Z Goldhaber (USA)
13:40 – 13:50	Management Strategies – Initial Anticoagulation Treatment and Secondary Prevention S Haas (Germany)
13:50 – 14:00	Cancer Associated Thrombosis in Everyday Practice J Weitz (Canada)
14:00 – 14:10	Outcomes in the Real World A G G Turpie (Canada)
14:10 – 14:25	Panel Discussion
14:25 – 14:30	Closing Remarks A K Kakkar (UK)

REGISTRATION

Please register for this programme by sending an email to events@tri-london.ac.uk

Please also join us at the Thrombosis Research Institute exhibition **Booth number: Hall 2.2 - Nr. 242** to find out more about GARFIELD-VTE.



The GARFIELD-VTE registry is an independent academic research initiative sponsored by the Thrombosis Research Institute (London, UK) and supported by an unrestricted research grant from Bayer AG (Berlin, Germany).

